Cat Media Pty Ltd v Allianz Australia Insurance Ltd
[2006] NSWSC 423
At a glance
Source factsCourt
Supreme Court of NSW
Decision date
2006-03-29
Before
Bergin J
Source
Original judgment source is linked above.
Judgment (55 paragraphs)
Background 1 On 28 April 2003 the licence of Pan Pharmaceuticals Limited (Pan) to manufacture non-sterile therapeutic goods for human use (the Licence) was suspended for a period of 6 months pursuant to s 41 of the Therapeutics Goods Act 1989 (Cth) (the Act) by notice signed by the Delegate of the Secretary of the Department of Health and Ageing (the Notice). The Notice advised that Pan (and/or a related entity) had breached conditions of the Licence and had failed to observe "Manufacturing Principles" (the Principles). 2 The Principles, determined from time to time by the Minister, are written principles to be observed in the manufacture of therapeutic goods for use in humans (s 36(1) of the Act). They relate, inter alia, to standards to be maintained and equipment to be used (s 36(2)(a)), procedures for quality assurance and control (s 36(2)(b)), manufacturing practices (s 36(2)(d)), and other matters relevant to the quality, safety and efficacy of therapeutic goods for use in humans that are manufactured in Australia (s 36(2)(e)). "Therapeutic goods" include goods that are, or are likely to be taken to be, for therapeutic use (s 3). "Therapeutic use" means "use in, or in connection with, (a) preventing, diagnosing, curing or alleviating a disease, ailment, defect or injury in persons or animals; or (b) influencing, inhibiting or modifying a physiological process in persons or animals; or (c) testing the susceptibility of persons or animals to a disease or ailment; or (d) influencing, controlling or preventing conception in persons; or (e) testing for pregnancy in persons; or (f) the replacement or modification of parts of the anatomy in persons or animals". 3 Pan carried on its business as a manufacturer of therapeutic goods at premises at 10-12 Church Street, Moorebank. It manufactured over the counter tablets (OTC); soft gelatine capsules; effervescent and vitamin tablets; topical creams; and consumable liquid preparations. The area of the warehouse in Moorebank was 9,935 square metres with a significant container and semi-trailer dock area (the Premises). The layout of the Premises included a soft gel hall, a soft gel bulk handling area, a coating area, a packaging line, a n area for packaging raw materials, a tabletting hall, an area for effervescent products and various other areas for quarantine, tabletting raw materials and consumables, powders, liquids and creams and soft gel raw materials. 4 The Therapeutic Goods Administration of the Commonwealth Department of Health & Aging (TGA) carried out an audit of Pan's premises pursuant to the provisions of the Act in February and April 2003 (the Audit). That Audit report included the following: 9.2 Re: Area cleaning (a) In the compression room T11, there were visible powder residues on the top of the machine (Fette 2200), the (bulk transfer) control cabinet and around the (bulk) transfer line connection point. · These residues were composed of two distinctly coloured powders ie beige and white. · While acknowledging that the status card indicated that the room was to cleaned (sic), this did not satisfactorily explain the presence of the two powder types. It was further noted: · The previous products were (in preceding order) · "Memo-plus" 84568←"Memo-plus" 84920 "Memo-plus" 84567←"Calcium Carbonate Plus" 84699. · The specification describes Memo-plus as "… beigex4…" and Calcium gluconate as "… whitex4…"